NWQ Investment Management Company LLC lifted its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 24.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,204,186 shares of the company’s stock after acquiring an additional 236,685 shares during the period. NWQ Investment Management Company LLC’s holdings in Teva Pharmaceutical Industries were worth $22,819,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Financial Counselors Inc. grew its position in Teva Pharmaceutical Industries by 28.8% in the 3rd quarter. Financial Counselors Inc. now owns 181,130 shares of the company’s stock valued at $3,188,000 after buying an additional 40,531 shares during the last quarter. Lockheed Martin Investment Management Co. purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $317,000. Stelac Advisory Services LLC purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $326,000. Bluestein R H & Co. purchased a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $269,000. Finally, New York State Common Retirement Fund grew its position in Teva Pharmaceutical Industries by 14.7% in the 3rd quarter. New York State Common Retirement Fund now owns 780,292 shares of the company’s stock valued at $13,733,000 after buying an additional 100,200 shares during the last quarter. Institutional investors and hedge funds own 58.22% of the company’s stock.
In related news, EVP Mark Sabag sold 5,050 shares of the business’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 7,636 shares of company stock valued at $149,390 in the last ninety days. Corporate insiders own 7.10% of the company’s stock.
A number of research firms recently weighed in on TEVA. BTIG Research lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating and set a $17.00 price objective on the stock. in a research report on Friday, February 2nd. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, February 8th. Leerink Swann lowered their price objective on shares of Teva Pharmaceutical Industries from $17.00 to $16.00 and set an “underperform” rating on the stock in a research report on Friday, February 9th. Piper Jaffray Companies lowered shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and set a $11.00 price objective on the stock. in a research report on Friday, February 9th. Finally, Cantor Fitzgerald set a $18.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research report on Wednesday, January 3rd. Ten research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $20.81.
Teva Pharmaceutical Industries Ltd (NYSE:TEVA) opened at $19.32 on Wednesday. The stock has a market capitalization of $19,829.10, a price-to-earnings ratio of 5.03, a PEG ratio of 1.69 and a beta of 0.65. The company has a debt-to-equity ratio of 1.91, a quick ratio of 0.58 and a current ratio of 0.86. Teva Pharmaceutical Industries Ltd has a one year low of $10.85 and a one year high of $34.51.
Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.43% and a negative net margin of 72.66%. The business’s revenue was down 15.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.38 EPS. research analysts forecast that Teva Pharmaceutical Industries Ltd will post 2.31 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/03/14/nwq-investment-management-company-llc-increases-stake-in-teva-pharmaceutical-industries-ltd-teva.html.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.